Compare BYAH & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYAH | VIVS |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 2.1M |
| IPO Year | 2023 | 2010 |
| Metric | BYAH | VIVS |
|---|---|---|
| Price | $2.17 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.8K | ★ 772.9K |
| Earning Date | 07-24-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,603,000.00 |
| Revenue This Year | N/A | $228,144.28 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.82 |
| 52 Week Low | $0.05 | $0.14 |
| 52 Week High | $6.64 | $3.40 |
| Indicator | BYAH | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 34.12 |
| Support Level | $1.97 | $0.14 |
| Resistance Level | $3.26 | $0.30 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 43.97 | 12.68 |
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.